Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.
Biodesix, Inc., a leading diagnostic company in lung disease, today announced a partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to bring a COVID-19 Droplet Digital PCR (ddPCR) test to the FDA for an Emergency Use Authorization (EUA) approval to support the escalating need for testing in the U.S.
Biodesix, Inc., a leading diagnostic company in lung cancer, today announced the realignment of their commercial executive team. Kieran O’Kane will be promoted to Chief Commercial Officer (CCO) and Bobbi Coffin, current Chief Marketing Officer, will become the Chief Growth Officer (CGO), effective immediately.
Biodesix, Inc. a leader in lung cancer diagnostics, is extending its blood-based testing portfolio with the release of the Nodify CDT™ test, designed to help physicians identify patients with lung nodules at high risk of lung cancer.
Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc.
Biodesix, Inc. and Streck, Inc. today announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
AVEO Oncology and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab. Learn More!
Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association. The company was honored at the 16th Annual CBSA Awards Dinner.
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML.
Biodesix, Inc., the leader in lung cancer diagnostic solutions, today announced that current Chief Operating Officer Scott Hutton will become Chief Executive Officer on January 1, 2020.
Biodesix, Inc. today announced that Tri-Star Health in Nashville, TN is the first hospital system in the U.S. to adopt the recently launched Nodify XL2™ proteomic nodule classifier for incidental lung nodule management.